[Journal for Immunotherapy of Cancer] Researchers identified CXCR2 as a potential therapeutic target linking metabolic reprogramming and immune suppression in neuroendocrine prostate cancer.

[Cell Reports Methods] Scientists developed a xeno-free and scaffold-free prostate organoid platform that supports epithelial and stromal differentiation from human iPSCs, while also enabling compartment-specific genetic manipulation within the epithelial lineage.

[Journal of Advanced Research] The authors investigated the effects of the osteogenic microenvironment on prostate cancer cells by constructing three-dimensional bioprinted in vitro co-culture models.

[JCI Insight] Investigators hypothesized that local prostate GH action may promote EMT and contribute to benign prostatic hyperplasia pathogenesis. GH-treated human primary prostate epithelial cells, normal prostate cells, and primary cell cultures derived from resected BPH specimens exhibited enhanced DNA damage and activated EMT.

[Oncogene] Researchers performed an in vivo screen using a custom metabolic CRISPR library in enzalutamide-treated xenografts and identified the pentose phosphate pathway enzyme ribulose-5-phosphate 3-epimerase (RPE) as a critical driver of enzalutamide resistance.

[BriaCell Therapeutics] BriaCell Therapeutics announced that the US FDA has completed its review of the Investigational New Drug application for Bria-PROS+ and issued a Study May Proceed letter, clearing the way for clinical evaluation of Bria-PROS+, its next generation, personalized, off-the-shelf, cell-based immunotherapy for prostate cancer.

[Labcorp] Labcorp announced the nationwide availability of Roche's VENTANA® PTEN RxDx Assay, the first immunohistochemistry companion diagnostic test approved by the US FDA, to determine PTEN protein loss in tumors of patients with prostate adenocarcinoma.

[Prostate Cancer and Prostatic Diseases] Itraconazole (ITZ) represents a potential adjunctive strategy to standard therapies within rationally designed, biomarker-stratified combination regimens for mCRPC. The authors evaluate the signaling pathways targeted by ITZ, barriers to its clinical translation, and opportunities for biomarker-driven combination therapy.

[Cancer Cell] Investigators identified the lipid kinase PIKfyve as overexpressed in neuroendocrine prostate cancer, functioning as a central node in a stress-adaptive lipid kinase axis that supports adaptation to persistent endoplasmic reticulum stress.

[Proceedings of the National Academy of Sciences of the United States of America] Scientists uncovered a mechanism by which Polo-like kinase 1 (PLK1), frequently overexpressed in prostate cancer, orchestrates a metabolic shift in serine and sphingolipid metabolism through phosphorylation of phosphoglycerate dehydrogenase (PHGDH).

[Cancer Cell] The authors showed that in colorectal cancer, cholinergic stimulation induces CHRM3/Gq-dependent NTN1 secretion from cancer-associated fibroblasts, which in turn enhances intratumor cholinergic innervation.

[Cell Metabolism] Researchers showed that the canonical anti-ferroptosis response mediated by GPX4 and SLC7A11 is dispensable for colorectal cancer growth and progression in both sporadic and colitis-associated cancer models.